Dr. Gideon Shapiro, trained as an organic chemist at the University of North Carolina, the University of California, Berkeley and the Federal Institute of Technology (ETH), is a seasoned drug hunter. He has a 30+ year professional career in drug discovery, development and drug program management.
Early in his career, Dr. Shapiro served as the head of the Alzheimer chemistry group at Sandoz, the company first responsible for discovering LSD and marketing psilocybin. He has also held senior roles at various other companies, including Novartis, developing novel CNS drugs. Later, he transitioned his career to founding and leading biopharmaceutical ventures including EraGen Biosciences (later acquired by Luminex) and Somatocor Pharmaceuticals.
Over the last 15-years, Dr. Shapiro has had a central role in drug discovery, development and corporate partnering efforts at Fidelity venture-backed companies, including EnVivo Pharmaceuticals, and played a leadership role in the invention and advancement of numerous CNS drugs that entered late stage clinical trials.
Dr. Shapiro spent the last several years as the Chief Science Officer at Rugen Therapeutics, a leading drug discovery company with a therapeutic goal to correct synaptic dysfunction using a form of ketamine.